| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Iota-conotoxin RXIA TFA targets voltage-gated sodium channel (VGSC) subtypes NaV1.2, NaV1.6, and NaV1.7. These channels are pore-forming proteins that are responsible for the initiation and propagation of action potentials in neurons. NaV1.7 is a well-established target for pain research, as it is involved in nociceptive signaling. NaV1.2 and NaV1.6 are also important for neuronal excitability in the central and peripheral nervous systems. Iota-conotoxin RXIA TFA acts as an agonist, meaning it activates these channels, which can lead to increased neuronal excitability.
|
|---|---|
| ln Vitro |
In vitro, Iota-conotoxin RXIA TFA is used as a tool to study the function of NaV1.2, NaV1.6, and NaV1.7 sodium channels. Its activity is assessed in electrophysiological assays using cells expressing these channels. As an agonist, it activates the channels, causing them to open. The compound's specificity for these subtypes makes it useful for dissecting their roles in neuronal excitability and pain signaling.
|
| ln Vivo |
In vivo activity data for Iota-conotoxin RXIA TFA are not available in the current scientific literature, as it is a toxin used primarily for in vitro research. As a conotoxin, it would be expected to have potent effects in vivo, but these are not typically studied.
|
| Enzyme Assay |
A standard protocol for assessing Iota-conotoxin RXIA TFA's activity involves expressing NaV1.2, NaV1.6, or NaV1.7 channels in Xenopus oocytes or mammalian cell lines. Whole-cell patch-clamp recordings are performed to measure sodium currents. The toxin is applied, and its effects on current amplitude and gating properties are analyzed.
|
| Cell Assay |
Iota-conotoxin RXIA TFA is not typically used in cell-based assays measuring cell viability. Its use is focused on electrophysiological studies of ion channel function.
|
| Animal Protocol |
Iota-conotoxin RXIA TFA is a toxin and is not used in animal models for therapeutic purposes. It is used for in vitro research on ion channels.
|
| ADME/Pharmacokinetics |
Iota-conotoxin RXIA TFA is a peptide toxin provided as a TFA salt. It is not a drug and its pharmacokinetic properties are not relevant.
|
| References | |
| Additional Infomation |
Iota-conotoxin RXIA TFA is a research-grade conotoxin used as an agonist of voltage-gated sodium channels NaV1.2, NaV1.6, and NaV1.7. It has not entered clinical trials and is not approved for any therapeutic indication. Its mechanism of action involves activation of these sodium channels. The compound is available exclusively for research purposes.
|
| Molecular Formula |
C212H310N54O69S8.XC2HF3O2
|
|---|---|
| Molecular Weight |
4975.57 (free base)
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
